Skip to content
Menu

Trevena, Inc. TRVN

Full chart Compare
Set alert

Price alert · TRVN

All alert types
0.00 USD 0.00 (+0.00%)

Regular-session close

0.012 Day range 0.012
0.0003 52-week range 0.066
YTD
-95.83%
1 year
-95.83%

 

No chart data for this range yet.
Market cap
431
EPS (ttm)
-2.20
Shares out
852.93K
Forward P/E
-0.09
YTD return
-95.83%
1-year return
-95.83%
50-day average
3.32
200-day average
8.10
Volume
210
Avg volume
199
Open
0.012
Previous close
0.0005
Day's range
0.012 – 0.012
52-week range
0.0003 – 0.066
Analysts
Buy
Price target
100.00 (+19999900.0%)

Key statistics

Short % of float
7.03%

Fundamental scorecard

5 of 25 checks passed on TRVN’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2024.

Financials — quick view

All financials
TRVN Revenue — quarterly 325.00K
TRVN Net income — quarterly -4.89M
TRVN EPS — quarterly -5.75

Earnings

TRVN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 20240.00-5.79——
Aug 8, 2024Jun 1, 2024-9.25-5.75+3.50+37.84%
May 15, 2024Mar 1, 2024-9.25-9.00+0.25+2.70%
Apr 1, 2024Dec 1, 2023-13.00-26.50-13.50-103.85%
Nov 14, 2023Sep 1, 20230.00-14.25——
Aug 14, 2023Jun 1, 2023-11.25-17.25-6.00-53.33%

Upgrades / downgrades

TRVN analyst upgrades and downgrades
DateFirmActionFromTo
May 16, 2023JMP SecuritiesreitMarket OutperformMarket Outperform
Mar 30, 2023HC Wainwright & Co.reit—Buy
Mar 30, 2023JMP Securitiesreit—Market Outperform

About Trevena, Inc.

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
trevena.com

News

Your note

Sign in to keep a note on TRVN — it syncs with the Stock Master app.

Insider holders

TRVN insider holders
InsiderRelationLatest transactionDateShares held
BOURDOW CARRIE LChief Executive OfficerStock Award(Grant)Dec 13, 2023642,923
DEMITRACK MARK AOfficerStock Award(Grant)Dec 13, 2023306,224
DRAKE PATRICIA MOfficerStock Award(Grant)Dec 13, 2023107,078
SHIN BARRYChief Financial OfficerStock Award(Grant)Dec 13, 2023308,821
YODER ROBERT T.OfficerStock Award(Grant)Dec 13, 2023158,877

Institution ownership

TRVN institution ownership
Holder% heldSharesValueReported
Renaissance Technologies, LLC1.33%182,152160.47KJun 29, 2023
Blackrock Inc.0.82%112,17398.82KJun 29, 2023
Vanguard Group Inc0.53%72,81264.15KJun 29, 2023
Geode Capital Management, LLC0.48%65,16757.41KJun 29, 2023
Simplex Trading, LLC0.27%37,59033.12KJun 29, 2023
Captrust Financial Advisors0.24%33,07629.14KJun 29, 2023

Fund ownership

TRVN fund ownership
Holder% heldSharesValueReported
Vanguard Extended Market Index Fund0.51%70,17661.83KJun 29, 2023
Fidelity Extended Market Index Fund0.24%33,09537.73KMay 30, 2023
Fidelity OTC Portfolio0.13%17,80615.49KAug 30, 2023
Fidelity Total Market Index Fund0.07%8,94610.20KMay 30, 2023
Fidelity NASDAQ Composite Index Fund0.05%7,4578.50KMay 30, 2023
Fidelity Series Total Market Index Fund0.05%7,3588.39KMay 30, 2023